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The E3 ubiquitin ligase Murine double minute 2 (MDM2) is the main negative regulator
of the tumor protein p53 (TP53). Extensive studies over more than two decades
have confirmed MDM2 oncogenic role through mechanisms both TP53-dependent and
TP53-independent oncogenic function. These studies have contributed to designate
MDM2 as a therapeutic target of choice for cancer treatment and the number
of patents for MDM2 antagonists has increased immensely over the last years.
However, the question of the physiological functions of MDM2 has not been fully
resolved yet, particularly when expressed and regulated physiologically in healthy tissue.
Cardiovascular complications are almost an inescapable side-effect of anti-cancer
therapies. While several MDM2 antagonists are entering phase I, II and even III of clinical
trials, this review proposes to bring awareness on the physiological role of MDM2 in the
cardiovascular system.
Keywords: murine double minute 2 (MDM2), cardiovascular health, intracellular signaling, cardiac, endothelial,
vascular smooth muscle cells
INTRODUCTION
Murine double minute 2 was identified in 1993 as a gene that is amplified in about one-
third of human soft tissue sarcomas (Leach et al., 1993). This E3 ubiquitin ligase is one of the
main negative regulators of the transcription factor tumor protein p53 (TP53). MDM2 regulates
TP53 activity through direct interaction and ubiquitination, repressing its transcriptional activity
Abbreviations: αMyHC, α-Myosin Heavy Chain; Akt, Protein Kinase B; ARC, apoptosis repressor with caspase recruitment
domain; ATM, ataxia telangiectasia mutated kinase; β-AR, β-adrenergic receptors; CaM, Ca2+/calmodulin; CaMKII-δ, CaM-
dependent protein kinase type II delta chain-δ; E2F1, E2 promoter binding Factor 1; ERK, extracellular signal-regulated
kinase; ESRR-β/γ, estrogen related receptor β/γ; FoxO, forkhead box O protein; GRK2, G protein-couple receptor kinase 2;
GSK3, Glycogen synthase Kinase 3; HDAC1, histone deacetylase 1; HIF1-α, hypoxia-inducible factor 1-α; HUVEC, human
umbilical vein endothelial cells; IGF1, Insulin-like growth factor 1; IGFR1, Insulin-like growth factor receptor 1; IRS1,
Insulin-receptor substrate 1; KK-Ay mice, crossbred of diabetic KK and lethal yellow mice carrying a heterozygous mutation
of the agouti gene; LDLr, low lipoprotein receptor; lincRNA-p21, Long intergenic non-coding RNA-p21; MAPK, Mitogen-
activated protein kinases; MDM2, Murine double minute 2; MR, mineralocorticoid receptors (MR); NF-κB, Nuclear Factor
κB; NICD1, intracellular domain of Notch1; NOTCH, neurogenic locus notch homolog protein; p55γ, PI3k regulatory
subunit p55 γ; Pdgfβ-Cre-ER, tamoxifen-inducible Cre recombinase under the control of the murine platelet derived
growth factor receptor β polypeptide promoter/enhancer regions; Pi, inorganic phosphate; PI3K, Phosphotidylinositol 3-
Kinase; PGC1-α, Peroxisome proliferator-activated receptor gamma coactivator 1-α; PIGF, placenta growth factor; PPAR-α/γ,
peroxisome proliferator-activated receptor α/γ; PTMs, Post-translational modifications; ROS, reactive oxygen species; RSK,
Ribosomal S6 Kinase; SM22α, Smooth Muscle Protein 22-α; Tip60, Histone acetyltransferase KAT5; TP53, Tumor protein
p53; VEGF-A, vascular endothelial growth factor A; VSMC, vascular smooth muscle cell.
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(Levine and Oren, 2009; Vousden and Prives, 2009; Bieging
et al., 2014). MDM2-TP53 interaction is highly regulated by
multiple PTMs of both proteins (Meek and Anderson, 2009;
Meek and Hupp, 2010), and through interactions with other
binding partners (Naski et al., 2009; Fåhraeus and Olivares-Illana,
2014). MDM2 also has TP53-independent oncogenic properties
(Bohlman and Manfredi, 2014, 2016). Thus, using antagonists
that would limit MDM2 action represents a valuable anti-cancer
approach, independently of the TP53 status of cancer cells
(Toledo and Wahl, 2006; Bohlman and Manfredi, 2014, 2016).
Most patents for MDM2 antagonists concern small molecule
inhibitors, e.g., Nutlin-3a and RG7112. Some of these molecules
are currently under phases I, II and III of clinical trials (Li
and Lozano, 2013; Bohlman and Manfredi, 2016; Burgess et al.,
2016). Since cardiovascular side effects of anti-cancer therapies
are a recurrent problem (Jain et al., 2017), characterizing the
cardiovascular function of MDM2 has become a pressing issue.
Here, we propose to review the current literature regarding
the cardiovascular function of MDM2. This review is divided
into three parts. The first part analyzes whether the network of
MDM2-interacting proteins plays a role in the cardiovascular
system. The second part summarizes the knowledge gained
from MDM2-transgenic mice. The last part examines the role
of MDM2 in endothelial cells, in vascular smooth muscle cells
(VSMCs) and in cardiomyocytes, some of the most important
cells of the cardiovascular system.
THE NETWORK OF
MDM2-INTERACTING PROTEINS AND
THE CARDIOVASCULAR SYSTEM
MDM2 is ubiquitous and regulates key cellular processes, such
as differentiation, DNA repair and synthesis, transcription,
intracellular trafficking, cell cycle, hypoxia signaling, apoptosis
and oxidative stress response. To achieve these functions, MDM2
acts on TP53 and a myriad of other downstream proteins
(Fåhraeus and Olivares-Illana, 2014). The activity of MDM2
is tightly regulated through PTMs that include ubiquitination,
SUMOylation, putative acetylation and phosphorylation
(Kubbutat et al., 1997; Iwakuma and Lozano, 2003; Meek
and Anderson, 2009; Marine and Lozano, 2009; Naski et al.,
2009; Meek and Hupp, 2010; Nag et al., 2013; Fåhraeus and
Olivares-Illana, 2014). As a proof of concept that the MDM2
network plays a role in the cardiovascular system, we discuss
here some evidence supporting the idea that upstream regulators
(see Table 1 for summary) and downstream targets (see Table 2
for summary) of MDM2 can regulate the homeostasis of vascular
beds and the cardiac tissue.
MDM2-Upstream Regulators
Several upstream regulators of MDM2 are important actors of
the cardiovascular homeostasis. To illustrate the idea, we have
deliberately chosen to discuss the role of a few receptors and
kinases (Figure 1).
We will first present how ligands relay their signals to MDM2
by discussing the role of two tyrosine kinases receptors, the
Vascular Endothelial Growth Factor Receptor (VEGFR2) and the
Insulin-like Growth Factor 1 Receptor (IGFR1), as well as one
G-protein coupled receptor, the β-Adrenergic Receptor (β-AR).
Kinases sensing DNA damage inhibit MDM2, while
growth factors activate MDM2 through the modulation of
phosphorylation on multiple sites: the nuclear localization
signal, the nuclear export signal, the acidic and central
domain (Figure 1). For example, growth factors stimulate
MDM2 functions by limiting glycogen synthase kinase-3
(GSK3)-dependent phosphorylation on the acidic domain
(Serines 240 and 254) and by enhancing Akt-dependent
phosphorylation (Serines 166 and 186). These actions of growth
factors counterbalance the effects of DNA damage kinases, such
as ATM which phosphorylates MDM2 on Serine 395 (Meek
and Anderson, 2009; Meek and Hupp, 2010). Therefore, we
will analyze the specific role of the ataxia telangiectasia mutated
(ATM) kinase, a DNA damage kinase, and the role of GSK3 and
Akt in the cardiovascular system.
Receptors Upstream of MDM2
The Vascular Endothelial Growth Factor-A (VEGF-A) is a very
potent stimulator of angiogenesis, crucial to maintaining vascular
homeostasis. VEGF-A binds to VEGFR2, a tyrosine kinase
receptor, leading to its activation by auto-phosphorylation.
Once activated, VEGFR2 relays its signal to downstream
kinases including the Phosphotidylinositol 3-Kinase/Akt
(PI3K/Akt) and the Mitogen-activated protein kinases (MAPKs)
(Claesson-Welsh, 2016). Both the PI3K/Akt and MAPK
pathways can phosphorylate MDM2 on serine residues 166
and 186 (Mayo and Donner, 2001; Feng et al., 2004; Hogan
et al., 2008) to promote the oncogenic function of MDM2
in cancer cells. In a physiological context, we reported
that VEGF-A promotes MDM2 phosphorylation. Indeed,
VEGF-A elicits MDM2 phosphorylation in the skeletal
muscle during physical exercise, as well as in primary
endothelial cells (Aiken et al., 2016) (for more detailed
information see Part 3 ‘Role of the MDM2 pathway in primary
endothelial cells’).
IGFR1 and β-AR are important for cellular processes in the
heart such as hypertrophy, contractility and cell survival (Stiles
et al., 1984; Weeks et al., 2017). Binding of IGF1 to its receptor,
IGFR1, promotes the phosphorylation of MDM2 through the Akt
and MAPK pathways. This leads to MDM2 nuclear localization
and enhances its stability and activity (Ogawara et al., 2002; Feng
et al., 2004; Worrall et al., 2017). B-adrenergic stimulation is
well known to activate both Akt and MAPK pathways (Morisco
et al., 2000; Vidal et al., 2012). Most recently, chronic exposure to
β-adrenergic agonist, isoproterenol, was reported to increase the
expression of ATM, a kinase upstream of MDM2 (Foster et al.,
2011). This suggests that MDM2 can sense the β-adrenergic and
IGF1 signals. Interestingly, several publications highlight a more
complex relationship. Indeed, MDM2 can regulate the trafficking
of both IGFR1 and β-AR, modulating the sensitivity of cells to the
IGF1 and catecholamines, respectively (Girnita et al., 2007; Jean-
Charles et al., 2017). The relationship between MDM2 and β-AR
is discussed in further detail in Part 3, ‘MDM2 and the regulation
of the β-adrenergic signal.’
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TABLE 1 | Summary of the putative cardiovascular functions of upstream regulatory kinases for MDM2 discussed in this review.
Kinase Sites phosphorylated Effect on MDM2 function Known or presumed cardiovascular function
DNA-PK Ser17 Limits MDM2-TP53 interaction Control of smooth muscle proliferation (Medunjanin et al., 2015;
Kinoshita et al., 2017)
Maintenance of endothelial cell quiescence (Mannell et al., 2010)
Increased level of myocardial expression in dilated cardiomyopathy
(Bartunek et al., 2002)
ERK1/2 Ser166 and Ser 186 Stabilizes MDM2, facilitates nuclear translocation Alterations of the ERK related pathway are involved in
cardiovascular pathogenesis (Muslin, 2008)
Akt/PKB Ser166 and Ser 186 Stabilizes MDM2, limits self-ubiquitination and
degradation, facilitates nuclear localization
Akt/PKB pathway is crucial regulator of cell survival, angiogenesis,
vasodilation, metabolism in the cardiovascular system (Abeyrathna
and Su, 2015)
Cyclin A/CDK2 Thr216 Promotes MDM2-TP53 interaction Control of cell cycle in the cardiovascular system (Stanley-Hasnain
et al., 2017)
GSK-3 Ser240 and Ser254 Limits MDM2-TP53 interaction, inhibition of TP53
ubiquitination and degradation
Regulates cardiac myocyte metabolism and controls cardiac
hypertrophy (Potz et al., 2016; Takahashi-Yanaga, 2018)
ATM Ser395 Reduces the capacity of MDM2 to facilitate the
nuclear-cytoplasmic translocation and
degradation of TP53
Control of pathological angiogenesis, involvement in
atherosclerosis, insulin resistance and cardiac remodeling and
sensing of β-adrenergic signals (Okuno et al., 2012; Espach et al.,
2015)
The few studies discussed above support the idea that MDM2
can relay the signals sensed by tyrosine kinase receptors and
G-protein coupled receptors within the cardiovascular system.
Yet, further investigations are warranted to fully elucidate how
these receptors regulate MDM2 functions.
Cardiovascular Function of Ataxia Telangiectasia
Mutated (ATM) Kinase
Patients with Ataxia telangiectasia syndrome not only present
growth retardation, premature aging and a high risk of cancer,
they also exhibit insulin resistance, glucose intolerance and a
higher risk of ischemic heart disease (Espach et al., 2015). This
suggests that ATM has cardiovascular functions. Interestingly,
ATM has emerged as a regulator of atherosclerosis and
potentially angiogenesis.
In the atherogenic environment of the Apo null background,
haplodeficient ATM± mice present the earliest onset of
atherosclerosis (Mercer et al., 2012). Haplodeficient ATM± mice
also have worse cardiac remodeling and an impaired ventricular
function post-myocardial infarction compared to their wild-
type littermate, suggesting that ATM depletion facilitates the
development of heart failure (Daniel et al., 2014, 2016; Jia
et al., 2017). This suggests a potential role for ATM in
maintaining cardiovascular health through the protection against
atherosclerosis and pathological cardiac remodeling. Beyond
these protective effects, ATM might regulate angiogenesis.
It is well known that in response to DNA damage, ATM
phosphorylates MDM2 on the Ser395 (de Toledo et al., 2000;
Gannon et al., 2012). After hypoxia-reoxygenation, reactive
oxygen species (ROS) activate ATM in immature blood vessels.
The activation of ATM represses the p38α MAPK. Usually, p38α
is activated by the VEGFR2 to support endothelial cell migration;
but when overactivated p38α can favor endothelial cell apoptosis.
ATM activity can limit p38α proapoptotic functions, thus
enhancing endothelial survival (Okuno et al., 2012). Through this
mechanism, ATM supports pathological angiogenesis in ischemic
retinopathy and tumor growth. Since ATM knock-out in the
whole body and specifically in the endothelium protects mice
from these pathological forms of angiogenesis, it appears that
ATM is a key regulator of angiogenesis driven by hypoxia and
oxidative stress. We have reported a central role for MDM2 in
muscle angiogenesis during endurance exercise (Roudier et al.,
2012; Aiken et al., 2016), a stress-associated oxidative stress and
potentially tissue hypoxia. Yet, it remains unknown whether the
angiogenic function of MDM2 is regulated by ATM.
A lot remains to be discovered regarding the cardiovascular
functions of ATM, however, this DNA damage kinase might
modulate how the cardiovascular system adapts to micro-
environmental stressors, such as oxidative stress, proatherogenic
factors and ischemia.
Growth Factor Responsive Kinases
Growth factors stimulate MDM2 in multiple ways, including the
downregulation of GSK3 and the activation of Akt. Interestingly,
both GSK3 and Akt play an important role in controlling cardiac
hypertrophy (Weeks et al., 2017; Takahashi-Yanaga, 2018).
GSK3 is ubiquitous and normally active in the absence of
growth factors. GSK3 phosphorylates the central domain of
MDM2, decreasing MDM2 actions on its targets, e.g., TP53
(Kulikov et al., 2005; Lin et al., 2012). To support cardiac function
during hypertrophy, it is crucial that angiogenesis occurs to
maintain proper blood supply to the cardiac muscle. Chemical
inhibition of GSK3 by IM-12 improves myocardial blood flow
recovery in pigs fed with a high-fat diet then subjected to
myocardial infarction induced by left circumflex coronary artery
constriction (Potz et al., 2016). Overall, the increased capillary
density suggests improved tissue perfusion. Unfortunately, the
capillary-to-cardiomyocytes ratio was not reported in this study.
The observed increase in myocardial capillary density could
be a result of reduced hypertrophy, since GSK3 is a negative
regulator of cardiac hypertrophy (Takahashi-Yanaga, 2018).
Indeed, reduced cardiomyocyte size would increase capillary
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TABLE 2 | Summary of the putative cardiovascular functions of downstream effectors of MDM2 discussed in this review.
Downstream effector Effect on downstream targets Known or presumed role of target in the
cardiovascular system
ARC, Apoptosis Repressor with
Caspases recruitment domain
MDM2 promotes the degradation of ARC ARC has anti-apoptotic function in cardiomyocytes and
skeletal muscles (Koseki et al., 1998)
β-arrestin MDM2 binds, interacts and ubiquitinates with β-arrestin 1
proteins.
Binding between β-arrestin1 and MDM2 restrains p53
activity (Hara et al., 2011, 2013)
MDM2 ubiquitination facilitates binding to signaling kinases
downstream of β-arrestin 2
Ubiquitination of β-arrestin is crucial to regulate
internalization and recycling of β-adrenergic receptors
(Shenoy et al., 2007; Jean-Charles et al., 2016)
E2F1, E2F transcription factor 1 MDM2 binding stimulates the activity of E2F1 E2F1 promotes cardiac dysfunction and increases the size
of infarction after myocardial infarction (MI).
E2F1 stabilizes TP53 and represses the expression of
VEGF-R2, facilitating apoptosis in endothelial cells and
inhibition of angiogenesis after MI (Wu et al., 2014)
FoxO1, Forkhead box protein
O1
MDM2 binds and interacts with FoxO1, triggering its
degradation by the proteasome
Endothelial FoxO1 promotes an angio-static environment in
ischemic tissue (Milkiewicz et al., 2011; Roudier et al., 2013)
FoxO1 expression supports diabetic cardiomyopathy
(Battiprolu et al., 2012; Qi et al., 2015; Chistiakov et al.,
2017)
FoxO1 limits endothelial cell migration (Aiken et al., 2016)
FoxO4, Forkhead box protein
O4
MDM2 favors both mono- and poly-ubiquination of FoxO4.
Mono-ubiquitination stabilizes FoxO4. Poly-ubiquitination
triggers FoxO4 degradation.
Endothelial FoxO4 promotes inflammation and cardiac
dysfunction after myocardial infarction (Zhu et al., 2015)
GRK2, G-protein-coupled
receptor kinase 2 (i.e.,
β-adrenergic receptor
kinases 1)
MDM2 ubiquitinates GRK2 triggering its proteasomal
degradation.
Absence of MDM2 regulation of GRK2 induces GRK2
stabilization, uncoupling of β-adrenergic receptor and G
protein, the β-adrenergic receptor stays in a desensitized
state (Jean-Charles et al., 2017)
HDAC1, histones deacetylase 1 MDM2 ubiquitinates HDCA1 Reduction of HDAC1 protein level by MDM2 supports
vascular calcification in vivo and in vitro in vascular smooth
muscle cells (Kwon et al., 2016)
HIF1-α, hypoxia-inducible
factor 1 α
MDM2 stabilizes HIF1α in an Akt-dependent manner Lack of HIF1-α during cardiac hypertrophy supports
transition to heart failure due to a lack of angiogenesis
(Sano et al., 2007; Toko et al., 2010)
NICD, Notch intracellular
domain
MDM2 interacts with and ubiquitinates NICD. MDM2
ubiquitination of NICD is an activation signal rather than a
trigger for degradation by the proteasome (Pettersson
et al., 2013).
Inhibition of endothelial NOTCH causes heart hypertrophy
and heart failure due to impaired transport of fatty acids and
altered blood vessel growth (Jabs et al., 2018)
TP53, tumor protein p53 MDM2 binding to p53 limits TP53 transcriptional activity. TP53 provokes transition from cardiac hypertrophy to heart
failure by promoting cardiomyocyte apoptosis and limiting
angiogenesis (Sano et al., 2007; Toko et al., 2010)
MDM2 ubiquitination triggers proteasomal degradation of
TP53
Preserving MDM2 action on p53 prevents ischemic limb
loss after femoral artery ligation (Morimoto et al., 2011)
TP53 limits vascular smooth muscle cells proliferation in a
pro-atherogenic environment (Hashimoto et al., 2011)
Tip60, Histone
acetyltransferase KAT5
MDM2 interacts with and ubiquitinates Tip60 triggering
Tip60 degradation
Tip60 regulates senescence, restrains cell cycle and is
required for survival in cardiomyocytes in response to
pressure overload (Fisher et al., 2012; Fisher et al., 2016;
Hu et al., 2009)
density without any gain of capillaries. Therefore, reporting
a capillary-to-cardiomyocytes ratio is crucial to demonstrate
whether angiogenesis occurred.
Growth factors induce Akt-dependent phosphorylation of
MDM2. This promotes MDM2 interaction with the HIF1-α,
stabilizing HIF1-α and enhancing its transcriptional activity
on pro-angiogenic genes (Mayo and Donner, 2001; Bárdos
et al., 2004). Akt-dependent phosphorylation of MDM2 facilitates
MDM2 interaction with TP53, leading to TP53 ubiquitination
and degradation. The resulting decrease in TP53 restrains
apoptosis and can favor angiogenesis by limiting angiostatic gene
expression, such as Thrombospondin-1 (Dameron et al., 1994). It
is worth noting that TP53 and HIF1-α can compete for binding to
MDM2, which means that under hypoxia HIF1-α could restrain
the capacity of MDM2 to inhibit TP53 (Robertson et al., 2014).
In the heart, Akt signaling coordinates the growth of
cardiomyocytes with angiogenesis to ensure the cardiac tissue
remains well perfused during physiological hypertrophy (Weeks
et al., 2017). Conversely, pathological hypertrophy promotes
TP53 expression. Cardiac hypertrophy induced by pressure
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FIGURE 1 | Diagram of MDM2 domains showing phosphorylation sites and upstream regulators (kinases and related receptors) of MDM2 functions, as well as
putative binding sites with downstream effectors. Top, most common phosphorylation sites on Serine (Ser) and Threonine (Thr) are indicated by a red pin. Residues
are numbered based on amino acid sequence from N-terminus to C-terminus. Middle, the functional domains of MDM2 include the hydrophobic pocket, the nuclear
localization sequence (NLS), the nuclear export sequence (NES), the acidic and central domain, the Zinc domain (Zn) and the ring domain (RING). Bottom, selected
interactions between MDM2 and its downstream effectors of MDM2 are illustrated. β-Adrenergic receptor, β-AR; DNA-dependent protein kinase, DNA-PK; E2F
transcription factor 1, E2F1; extracellular-signal-regulated kinase, ERK; Forkhead box protein, FoxO; herpes virus-associated ubiquitin specific protease, HAUSP;
Insulin-like growth factor receptor 1, IGFR1; Mitogen-activated protein kinases, MAPK; Mouse double Minute 4, MDM4; NUMB; Notch intracellular domain, NICD;
Phosphotidylinositol 3-kinase, PI3K; Protein kinase B, PKB; protein numb homolog, Retinoblastoma protein, RB; Vascular Endothelial Growth Factor Receptor 2,
VEGFR2.
overload leads to TP53 accumulation, restriction of HIF1-
α functions and a lack of angiogenesis (Sano et al., 2007);
a similar outcome was observed in the failing heart (Toko
et al., 2010). While it remains unknown whether Akt-dependent
phosphorylation of MDM2 plays a role in these pathological
changes in TP53 and HIF1-α, a study suggests that increased
MDM2 activity could be beneficial. Indeed, overexpression of
IGF1 in vitro and in vivo enhanced MDM2 activity toward
TP53 in cardiomyocytes preventing apoptosis and the activation
of the renin-angiotensin system, a hallmark of heart failure
(Leri et al., 1999a,b).
In the KK-Ay diabetic mice, atorvastatin, a cholesterol-
lowering drug, preserved the insulin sensitivity of Akt in the
lower limb after femoral artery ligation. Atorvastatin increased
the levels of Serine 166 phosphorylation and prevented TP53
accumulation in the ischemic lower limb. Since atorvastatin
rescued limb loss after femoral artery ligation. These data
suggest that activation of MDM2 supports limb recovery
(Morimoto et al., 2011).
GSK3 seems to support adverse remodeling after
myocardial infarction, while Akt facilitates beneficial
adaptations. Additional investigations are required to fully
comprehend how GSK3 and Akt impact MDM2 function
in the context of these cardiovascular diseases. Together
these studies, however, clearly support that kinases upstream
of MDM2 play a role in controlling the balance between
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microvascular content and striated muscle hypertrophy during
pathological remodeling.
MDM2-Downstream Targets
MDM2’s functions go beyond the old paradigm that MDM2
is a key regulator of transcriptional factor TP53. Indeed,
this E3 ubiquitin ligase has numerous targets in all cellular
compartments. Therefore, we have chosen to discuss several
examples of MDM2 targets, including some nuclear proteins
involved in the regulation of gene expression and several
cytoplasmic proteins involved in key intracellular signaling and
trafficking pathways.
Nuclear Downstream Targets of MDM2
MDM2-FoxO proteins interaction
We and others have reported that MDM2 is key regulator of
FoxO transcription factors (van der Horst et al., 2006; Brenkman
et al., 2008; Yang J.-Y. et al., 2008; Yang W. et al., 2008; Fu
et al., 2009; Aiken et al., 2016). The original observation that
FoxOs are important for longevity (Salih and Brunet, 2008),
led researchers to explore the cardiovascular functions of FoxO.
FoxO proteins are well-known regulators of antioxidant defense.
With no exception, FoxO1 and FoxO3 have been reported to be
important to maintain antioxidant molecules (i.e., catalase and
SOD2) in response to cardiac ischemia-reperfusion (Sengupta
et al., 2011; Puthanveetil et al., 2013). Due to this function,
FoxO proteins were thought to have protective properties in
the cardiovascular system. However, this might be context- and
tissue-dependent.
In the vasculature, endothelial knock-down of FoxO1, FoxO3
and FoxO4 appears to be protective against atherosclerosis in
LDLr−/− mice, a transgenic mouse model that creates a pro-
atherogenic environment due to a lack of low-density lipoprotein
receptors (LDLr) (Tsuchiya et al., 2012). This supports the
detrimental role of FoxO protein in arteries exposed to an
atherogenic environment. Mouse models of type 2 diabetes
present increased levels of cardiac FoxO1 (Battiprolu et al.,
2012; Qi et al., 2015; Chistiakov et al., 2017). This increase
in FoxO1 downregulates insulin receptor substrate 1 (IRS-1)
impairing Akt activity and insulin sensitivity. Cardiac-specific
knock-down of FoxO1 prevented the development of diabetic
cardiomyopathy, making a strong case for a detrimental role
of cardiac FoxO1 during diabetic cardiomyopathy. FoxO1,
β-arrestin, IRS and IGF1R are all crucial to maintaining an
efficient insulin signal (Usui et al., 2004; Girnita et al., 2007).
Interestingly, these proteins might compete for binding to
MDM2 (Balaji et al., 2018). Yet, the role of cardiac MDM2
in diabetic cardiomyopathy remains unclear. In the context
of post-myocardial infarction, endothelial-specific depletion
of FoxO4 improved cardiac function by preventing loss of
nitric oxide production. Maintenance of nitric oxide restrained
inflammation by suppressing monocyte adhesion (Zhu et al.,
2015). Interestingly, MDM2 is upregulated in the cardiac
tissue 24 h post-myocardial infarction and remains elevated
up to 4 weeks post-infarction (Zhao et al., 2016). MDM2
inhibition by Nutlin-3a improved survival and repressed the
inflammatory response in this context. MDM2 has been reported
to prime the mono-ubiquitination of FoxO4 in response to
oxidative stress (Brenkman et al., 2008) leading to FoxO4 poly-
ubiquitination and degradation when MDM2 levels are high
(Hauck et al., 2017). It is then appealing to hypothesize that
the interaction between MDM2 and FoxO4 in the endothelium
controls the inflammatory response after myocardial infarction;
a hypothesis that remains unverified. Finally, we reported an
upregulation of FoxO1 in ischemic skeletal muscle during
peripheral artery disease (Milkiewicz et al., 2011; Roudier et al.,
2013) that correlated with a restrained binding between MDM2
and FoxO1. Endothelial-directed depletion of FoxO1 enhanced
angiogenesis (Milkiewicz et al., 2011). Since constitutive active
MDM2 reduces FoxO1 transcriptional activity in endothelial cells
(Aiken et al., 2016), it is appealing to hypothesize that MDM2
impedes the angiostatic function of FoxO1 in the endothelium.
Based on the above studies it appears that an in-depth analysis
of the FoxO-MDM2 interaction in the cardiovascular tissues has
the potential to help fully comprehend how the FoxO functions
(i.e., antioxidant defense, angiostasis, inflammation, etc.) are
regulated during cardiovascular diseases.
MDM2, E2F1 and the ischemic heart
E2 promoter binding Factor 1 (E2F1) is a transcriptional
activator mainly known to regulate the cell cycle, apoptosis
and angiogenesis to support tumor progression (Schaal et al.,
2014). MDM2 was shown to stimulate E2F1 transcriptional
activity in tumors (Martin et al., 2014), potentially shifting
E2F1 properties from antiproliferative to proliferative (Loughran
and Thangue, 2000). Interestingly, E2F1-deficient mice show
improved cardiac function, reduced size of myocardial infarction,
and enhanced post-infarction cardiac angiogenesis after ligation
of the left anterior descending coronary artery. These beneficial
effects of E2F1 deficiency in the ischemic heart were due to an
upregulation of pro-angiogenic factors (i.e., vascular endothelial
growth factor A, VEGF-A and placental growth factor, PIGF
(Wu et al., 2014). In cardiac fibroblasts subjected to hypoxia, the
overexpression of E2F1 increased the expression of TP53, which
was required to repress the expression VEGF-A; while a decrease
in PIGF occurred independently of the TP53 status of these
cells. These results suggested that E2F1 promotes the expression
of pro-angiogenic factors through both TP53-dependent and
TP53 independent mechanisms (Wu et al., 2014). Conversely to
previous observations made in tumor cells, MDM2-deficiency
in cardiac cells was reported to enhance E2F1 transcriptional
activity and to have detrimental effects on the heart homeostasis
(Hauck et al., 2017) (see below Part ‘Insight from MDM2
transgenic mice’). Further investigations are thus warranted to
better understand how the interplay between MDM2 and E2F1
impacts myocardial physiology and recovery post-infarction.
MDM2, Tip60, and cardiac hypertrophy
Tip60 is an acetyltransferase that acetylates histones and
other proteins, including TP53 and ATM. When TP53 is
acetylated on lysine 120 by Tip60, it triggers TP53-dependent
apoptosis (Tang et al., 2006). MDM2 can interact with
Tip60. MDM2 promotes the proteasomal degradation of
Tip60 (Legube et al., 2002), whereas Tip60 binding to
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MDM2 restrains the neddylation capacity of the E3 ligase
(Dohmesen et al., 2008). Tip60 expression in cardiac tissue is
enriched during early cardiac development and adult hearts
are reported to express Tip60 (Lough, 2002; Hu et al.,
2009; Fisher et al., 2012, 2016). Tip60± heterozygous mice
(12–14 week-old) present an enhanced cell cycle activity
and reduced apoptosis, that could support better cardiac
regeneration in the heart subjected to pressure-overload
(Fisher et al., 2012).
Specific depletion of Tip60 in cardiomyocytes in mice
increased cardiomyocyte cell cycling in vivo in 2–4 week-old
hearts (Fisher et al., 2016). However, this was followed by a
significant loss of cardiomyocytes after 8 weeks, a reduction of
heart mass leading to death between 8 and 12 weeks of age due to
cardiac dysfunction. Together these results suggest that Tip60 is
crucial to control the balance between cell cycle and apoptosis
in the myocardial cells. Yet, the role of MDM2 on the cardiac
functions of Tip60 remains to be studied.
Cytoplasmic Downstream Targets of MDM2
MDM2, endothelial Notch and cardiac hypertrophy
The NOTCH pathway acts conjunctly with Vascular Endothelial
Growth Factor-A (VEGF-A) to allow patterning of blood
vessels during sprouting angiogenesis (Blanco and Gerhardt,
2013). This is essential for vascular growth. An elegant study
by Jabs et al. (2018) recently demonstrated the role of the
NOTCH pathway in the adult endothelium of the heart.
Endothelial-specific downregulation of NOTCH1 signal was
induced by conditional ablation of the Rbp-jκ complex in adult
mice. In this model, restriction of the endothelial NOTCH
pathway was highly associated with cardiac dysfunction,
cardiac hypertrophy and impairment of fatty acid transport
through the endothelium. The source of energy shifted
in favor of glucose instead of fatty acids, likely limiting
the capacity to supply ATP for cardiac function. All these
changes are hallmarks of heart failure. Down-regulation
of the NOTCH pathway was associated with an increase
of cardiac microvascular density, supporting the idea that
NOTCH imposes a brake on cardiac angiogenesis (Jabs et al.,
2018). Usually improved cardiac angiogenesis is associated
with physiological cardiac hypertrophy. The observation
that enhanced angiogenesis led to heart failure supports the
idea that the growth of an abnormal vascular bed occurs
when NOTCH is inhibited. The main negative regulator
NOTCH1 is NUMB. Indeed, NUMB facilitates NOTCH1
ubiquitination and degradation. MDM2 positively regulates
the NOTCH signaling pathways through its capacity to
bind to both NUMB and to the NICD1. MDM2 promotes
the degradation of NUMB, an event that could enhance
NOTCH1 signaling. Conversely, MDM2 binds to the NICD1.
This binding does not promote the ubiquitination nor the
degradation of NOTCH1, but rather it activates the NOTCH
signaling pathway, in cancer cell lines (Pettersson et al.,
2013). Since we and others have reported pro-angiogenic
functions of MDM2 (Secchiero et al., 2007; Roudier et al.,
2012), further investigations are required to decrypt the
mechanisms controlling endothelial NOTCH activity in
the adult heart, studying the putative involvement of
MDM2 might bring new insight on how a normal cardiac
microvasculature is established.
MDM2 and beta-adrenergic pathway
MDM2 is associated with key regulators of the beta-adrenergic
pathway through its capacity to interact with β-arrestin, a protein
adapter of G protein-coupled receptor and G Protein-Coupled
Receptor Kinase 2 (GRK2) (Jean-Charles et al., 2017). The
pivotal work done by Hara et al. (2011, 2013) clearly established
that chronic exposure to β-adrenergic catecholamines facilitates
MDM2-β-arrestin1 interaction, restraining TP53 activity. One
consequence could be an impairment of the DNA damage
response with a potential impact on genomic integrity (Hara
et al., 2013). Additional works also support the idea that
MDM2 might function to recycle G protein-coupled receptors;
playing a key role in the desensitization and re-sensitization of
these receptors, including the β-AR (Wang et al., 2003; Shenoy
et al., 2009; Jean-Charles et al., 2016, 2017). Ultimately, this is
supportive of a role for MDM2 in the cardiovascular system
through the modulation of the cardiac response to β-adrenergic
stimulation (Cannavo et al., 2013).
Summary of “MDM2’s Social Network”
and the Cardiovascular System
The studies presented above, while not exhaustive, serve as
examples to highlight the diverse role of MDM2 as a central
hub in the cardiovascular system. Most human cardiovascular
diseases are associated with DNA damage due to oxidative stress
(Jackson and Bartek, 2009; Shimizu et al., 2014; Uryga et al., 2016)
and alteration of hormonal signals (Higashi et al., 2019). The
DNA damage kinase ATM is an upstream regulator of MDM2,
and it does modulate the endothelial function, playing a role
in atherosclerosis and angiogenesis. Growth factor responsive
kinases known to phosphorylate MDM2 appears as crucial
for a proper balance between vascularization and hypertrophy
during cardiac remodeling. MDM2 cardiovascular functions are
likely TP53- and HIF1-α-dependent, however, numerous TP53-
independent MDM2 binding partners also emerge as key actors
of cardiac and vascular homeostasis. Yet, a lot remains to be
done to fully understand how the “MDM2 social network”
participates in cardiovascular homeostasis over the lifespan
(Fåhraeus and Olivares-Illana, 2014).
PART 2: INSIGHT FROM THE MDM2
TRANSGENIC MICE
The phenotypic analyses of MDM2 transgenic mouse
models further demonstrate a crucial role for MDM2 in the
cardiovascular system (Table 3).
Vascular Phenotype and MDM2
Over the last two decades, several transgenic mouse models
have been generated to study the function of MDM2, revealing
a crucial role of MDM2 in supporting survival, as well as
vascular function.
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TABLE 3 | Description and summary of the cardiovascular phenotypes observed in MDM2 transgenic mouse model.
Transgenic mice
model
Type of genetic modification Site of transgenic
modification
Cardiac or vascular phenotype
MDM2-null MDM2 null mice. MDM2 mutant lacking
exon 10–12 or 7–12 were.
Whole body Embryonic lethality occurs before cardiac development
(Jones et al., 1995; Montes de Oca Luna et al., 1995)
MDM2 transgenic mice Full length MDM2 overexpression under
the control of its native promoter region.
fourfold increase in MDM2 mRNA
expression.
MDM2 transgenic mice were generated
in both p53 wild-type and p53-null
backgrounds
Whole body Independent of p53 background, mice with MDM2
transgene have a higher proportion of hemangiosarcoma
than p53-null mice with normal levels of MDM2 (Jones
et al., 1998).
Hypomorphic MDM2
mice
Downregulation of protein expression
by 70% using a hypomorphic allele
MDM2puro and a recombined null allele
MDM21 7−9 (Mendrysa et al., 2003)
Whole body Capillary rarefaction and lack of angiogenesis in response
to physiological stimulus in the skeletal muscle (Roudier
et al., 2012)
Enhanced cardiac/cardiomyocyte hypertrophy, and
increased alteration of myocardial tissue and function after
ischemia (Toth et al., 2006)
Endothelial MDM2-KO
mice
Tie2-Cre driven knock-down of MDM2
in endothelial cell lineage
Endothelial lineage cells Embryonic lethality at E10.5 due to vascular remodeling
defect, i.e., enlargement of the aortic lumen, the cardinal
veins and the extraembryonic vasculature (Zhang et al.,
2014).
Cardiomyocyte
MDM2-KO mice
αMyHC-Cre transgene was used to
induce MDM2 deletion in
cardiomyocytes
Cardiomyocytes Embryonic lethality at E9.5 failure to develop a functional
heart (Grier et al., 2006)
Inducible Endothelial
MDM2-KO mice
i-EC-MDM2KO
Cross breeding of Pdgfb-Cre-ER mice
with mice harboring the floxed MDM2
alleles
Induction of endothelial-specific
MDM2 deletion by tamoxifen
Abnormal swelling of animals 5 days after the injection of
tamoxifen
Death of all i-EC-MDM2-KO mice 16 days after tamoxifen
injection (Yokoyama et al., 2019)
Inducible
Cardiomyocyte specific
MDM2-KO mice
Cardiac muscle a-myosin heavy chain 6
promoter drives the expression of Cre
under the control of Tamoxifen
Tg(Myh6-Cre/Esr1)
Induction of cardiomyocytes
deletion by hydroxytamoxifen.
Cardiomyocytes-specific deletion of MDM2 lead to
spontaneous concentric hypertrophy and cardiac
dysfunction and early mortality (Hauck et al., 2017).
Inducible smooth
muscle specific
MDM2-KO mice
i-SMC-MDM2-KO mice
Cross breeding of SMC-specific SM22
promoter (SM-CreERT2) mice with mice
harboring the floxed MDM2 alleles
Induction of smooth muscle
cell-specific MDM2 deletion by
tamoxifen
Cre activity was not found in the cardiovascular system nor
in the aorta.
Death of all i-SMC-MDM2-KO mice 12 day post tamoxifen
injection due to gastrointestinal alterations (Boesten et al.,
2006).
Full Mdm2 deletion results in embryonic lethality at E5 (Jones
et al., 1995; Montes de Oca Luna et al., 1995). Embryonic lethality
was completely reversed in double-null mice, harboring both
MDM2 and TP53 deficiency (Mdm2−/− and Trp53−/−). Due
to the early stage of lethality, these initial studies did not allow
for the examination of MDM2 function in adult cardiac tissue.
To override the lethality observed in mice with full MDM2
knock-down, Zhang et al. (2012) created a transgenic mouse
with a selective knock-down of MDM2 in the endothelial cell
lineage using the Tie2-Cre transgene. The loss of endothelial
MDM2 also resulted in embryonic lethality, however, at a
later stage (E10.5). This lethality was due to defective vascular
patterning, including an enlargement of the aorta, the cardinal
veins, and the extraembryonic vasculature (Zhang et al., 2014).
The expression of TP53 targets genes, p21, Nuxa and Puma,
was increased at E8.5 and E9.0 in heart tube and apoptosis
was enhanced. Most recently, to study the role of MDM2 in
the adult endothelium, Yokoyama et al. (2019) generated a
transgenic mouse model in which the inducible endothelial cell-
specific depletion of MDM2 was achieved by tamoxifen injection
using the Pdgfb-Cre-ER transgene in 8-week old mice. Five days
after the injection of tamoxifen, some abnormal swelling was
observed in mice with endothelial-specific deletion of Mdm2. All
mice died 16 days post-injection. This phenotype was associated
with severe increases in TP53 expression and apoptosis in the
vascular bed, including in the skeletal muscle and the heart.
MDM2 appeared as crucial to maintain the vascular barrier
and permeability function of the endothelium. Taken together,
these studies present a strong case that in the embryo and in
adult mice, MDM2 acts in a TP53-dependent manner to limit
excessive TP53 overactivation and apoptosis in tissues, including
in the endothelium.
While the primary function of MDM2 might be to
restrain TP53, additional evidence supports the idea that
MDM2 is important for vascular homeostasis due to TP53-
independent functions. MDM2 overexpression in mice elicits
tumor formation, bringing irrefutable evidence that MDM2
promotes cancer development. A close phenotypic analysis of
these mice also reveals an endothelial function of MDM2.
The mice overexpressing MDM2 in a Trp53 null background
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presented a unique subset of tumors compared to mice
overexpressing MDM2 in a Trp53 wild-type background. Under
a Trp53 null background, a higher rate of hemangiosarcoma
was observed. This type of tumor is due to an uncontrolled
proliferation of endothelial cells (Jones et al., 1998). These
observations suggest that MDM2 can support endothelial cell
proliferation independently of simply controlling TP53 activity.
Another very interesting transgenic rodent model is the
hypomorphic Mdm2puro/1 7−9 mouse. These mice harbor one
hypomorphic allele (puro) and one null allele (17-9), thus
leading to a reduction of MDM2 expression by 70% of the normal
level of expression in tissue (Mendrysa et al., 2003). Under
basal conditions, these mice do not present TP53 overactivation.
Mdm2 hypomorphic mice, however, have a reduction in MDM2
activity. We reported a decrease of the capillary to fiber ratio
by 20% in the skeletal muscle of the hypomorphic Mdm2puro/1
7−9 mice (Ogawara et al., 2002) independently of TP53 status
(Ogawara et al., 2002). In response to endurance training,
a well-established powerful physiological stimulus for muscle
angiogenesis, the development of new blood vessels was blunted
in exercising Mdm2puro/1 7−9 mice. This shows that normal
expression of MDM2 is required both for the maintenance and
the expansion of the vascular bed. These studies support the
notion that beyond its primary function to keep TP53 under
control, MDM2 has TP53-independent vascular functions that
impact the capacity of endothelial cells to proliferate and to
initiate angiogenesis.
The smooth muscle tissue is another key component of blood
vessels. Mice with smooth muscle-specific MDM2 deficiency
have been generated using a tamoxifen-inducible Cre under the
control of the SM22 promoter (Boesten et al., 2006). These mice
died shortly (9–13 days) after the induction of MDM2 depletion
in the smooth muscle. However, the depletion of MDM2 in the
aorta was not be achieved with this approach, the author did
not investigate potential depletion in other vascular structures
(i.e., arterioles). So, it remains impossible to conclude regarding
the in vivo role of MDM2 in the vascular smooth muscle. The
putative role of MDM2 in cultivated VSMCs is discussed in Part
3 of this review.
Cardiac Phenotype and MDM2
MDM2 appears to be crucial for the embryonic development
of the heart. Tissue-specific loss of MDM2 in cardiomyocytes
induced by the αMyHC-Cre transgene results in embryonic
lethality. At E9.5, embryos with cardiomyocyte-specific Mdm2
deletion failed to develop a functional heart (Grier et al., 2006).
Immunohistochemistry staining of cardiomyocytes revealed a
significant thinning of the myocardial layer of the ventricles
and overall a much smaller heart weight, probably due to an
increased level of apoptosis. By E13.5, no embryos survived,
and most of them lacked visible signs of heart development
(Grier et al., 2006).
Interestingly, hypomorphic Mdm2puro/17−9 mice present a
lower heart weight, supporting the notion that MDM2 is required
to maintain heart mass. However, the heart-to-body mass ratio,
as well as the cardiomyocyte cross-sectional area were increased
in the hypomorphic mice (Toth et al., 2006). These mice were
also more sensitive to ischemia-induced damage presenting an
increased infarction area and an impaired cardiac function
(Toth et al., 2006). To study specifically the function of MDM2
in the adult heart, Hauck et al. (2017) generated mice with
a cardiomyocyte-specific inducible depletion of Mdm2. This
ablation of Mdm2 in the cardiomyocytes led to left ventricular
dysfunction and concentric remodeling of the heart, as shown
by a 98% increase in the heart-to-body mass and a 1.9-fold
increase in cardiomyocyte size 18 days after 4-hydroxytamoxifen
injection (Hauck et al., 2017). Mitochondrial dysfunctions were
also observed due to a lack of proper mitochondria biogenesis.
These mitochondrial effects were a consequence of alterations
in the transcription of TP53-dependent genes involved in
mitochondria energy metabolism (Pgc1-α, Ppar-α/γ and Esrr-
β/γ) (Hauck et al., 2017). Interestingly, Mdm2 mRNA levels were
found to be reduced in patients with ischemic cardiomyopathy,
idiopathic dilated cardiomyopathy and chemotherapy-induced
cardiomyopathy (Toth et al., 2006). Together these data support
the idea that reduced expression of MDM2 may facilitate
cardiomyocyte hypertrophy and cardiac hypertrophy.
Summary of Knowledge Gained From
MDM2-Transgenic Mouse Models
In the embryo, MDM2 is essential to both the cardiac and
endothelial tissue development with a primary role as a negative
regulator of TP53-induced apoptosis. In adult mice, MDM2
appears essential for controlling cardiac hypertrophy, potentially
through TP53 dependent mechanisms (Toth et al., 2006; Hauck
et al., 2017). Loss of MDM2 in the endothelium is lethal in
adult mice due to TP53 overactivation. However, MDM2 appears
to have TP53-independent functions that regulate vascular
homeostasis. Too little expression of MDM2 supports vascular
rarefaction and lack of angiogenesis, while excessive expression
leads to an uncontrolled expansion of the vascular bed.
PART 3: MDM2 FUNCTION AND THE
CARDIOVASCULAR CELLS
Aside from the phenotypic observations in transgenic mouse
models, evidence for a cardiovascular role of MDM2 is
also supported by studies that have investigated MDM2
and its signaling pathways in endothelial cells, VSMCs
and cardiomyocytes.
Role of the MDM2 Pathway in Primary
Endothelial Cells
Endothelial cells form the inner lining of blood vessels. In
these cells and MDM2 acts as a negative regulator of TP53,
limiting apoptosis (Dai et al., 2012; Brockhaus et al., 2018; Si
et al., 2018; Yokoyama et al., 2019). MDM2 could elicit other
endothelial functions. Originally, the interest in studying MDM2
in the endothelial cells was initiated by the observation that
MDM2 could enhance the production of pro-angiogenic factors
in tumor cells. Through its interaction with HIF-1α, MDM2
facilitates angiogenesis by stimulating the expression of VEGF-A
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in response to hypoxia and growth factors (Skinner et al., 2004;
Alam et al., 2009; Park et al., 2011; Patterson et al., 2011).
MDM2 might have a similar role in endothelial cells (Song
et al., 2012). Since autocrine VEGF-A is crucial to endothelial
cell survival (Lee et al., 2007), it is plausible that MDM2 also
supports endothelial cell survival through a VEGF-dependent
pathway. During angiogenesis, endothelial cells switch rapidly
from a quiescent state to a migratory and proliferative state.
The observation made by Seccherio and colleagues (2007) that
MDM2 antagonist Nutlin-3 inhibits cell cycle progression and
cell migration in HUVEC was one of the first lines of evidence
that MDM2 could facilitate the activation of endothelial cells
to support tumor angiogenesis. Interestingly in this study, the
author reported that tumor angiogenesis was inhibited by nutlin-
3 independently of TP53. This is an additional piece of evidence
that MDM2 angiogenic function might be independent of TP53.
We have observed in primary human and mouse endothelial
cells that the MDM2 signaling pathway is highly sensitive
to pro-angiogenic stimuli. Shear stress, VEGF-A and serum
stimulation increased the phosphorylation of MDM2 on Serine
166 (Milkiewicz et al., 2011; Aiken et al., 2016). By expressing
the phospho-mimetic form of MDM2 in primary endothelial
cells, we showed that Ser166 phosphorylation restrained the
expression of FoxO1 target genes known to promote angiostasis,
such as Sprouty-2 and Thrombospondin-1 and stimulated
endothelial migration (Aiken et al., 2016). In primary endothelial
cells, we have found that FoxO1 directly binds to MDM2,
an interaction that is increased by shear stress and serum
stimulation and correlates with decreased levels of FoxO1 protein
(Milkiewicz et al., 2011).
Together these studies support an important role of MDM2 in
endothelial cells to maintain survival and to support endothelial
responsiveness to pro-angiogenic stimuli.
Role of the MDM2 Pathway in Vascular
Smooth Muscle Cells
MDM2-p53 Interaction in Smooth Muscle Cells
The interest in studying the role of MDM2 in vascular smooth
cells has emerged from the observation that TP53 inactivation
stimulates atherosclerosis (Ihling et al., 1998; Mercer et al., 2005;
Mercer and Bennett, 2006). Atherosclerosis is characterized by
inflammation and excessive proliferation of VSMCs into the
tunica intima. Hashimoto et al. (2011) have clearly demonstrated
that disruption of MDM2-TP53 interaction restrained neointimal
hyperplasia following vascular injury. Treatment with the
small molecule MDM2 antagonist Nutlin-3 suppresses VSMC
proliferation and migration. Nutlin-3 promoted cell cycle arrest
in G1 in a TP53-dependent manner. In vivo Nutlin-3 treatment
significantly reduced the intima area and the intimal/media area
ratio after vascular injury compared to untreated animals. Nutlin-
3 treatment also led to lower levels of inflammation in response to
Tumor Necrosis Factor-α (TNF-α). This suggests that inhibition
of MDM2 prevented inflammation by restoring the capacity of
TP53 to inactivate the NF-κB (Hashimoto et al., 2011).
This pivotal work has been followed by other studies that
confirmed that inhibition of MDM2-TP53 interaction can
prevent the proliferation of VSMCs. Wu et al. (2014) have
demonstrated that the Long intervening non-coding-RNA p21
(LincRNA-p21) and TP53 compete for binding to MDM2 in
VSMCs. LincRNA-p21 binding to the RING domain of MDM2
facilitates TP53-p300 interaction, increasing TP53 transcriptional
activity in VSMCs. LincRNA-p21 expression appeared to be
significantly reduced in atherosclerotic plaque of ApoE−/− mice
and in coronary arteries of patients with coronary artery disease.
In vitro, silencing lincRNA-p21 using siRNAs significantly
increased cell viability and proliferation. And in vivo, knockdown
of lincRNA-p21 in ApoE−/− mice favored the interaction
between MDM2 and TP53 and facilitated neointimal hyperplasia.
Additionally, Li et al. (2015) have shown that p55γ, a regulatory
subunit of PI3K, inhibited the ubiquitination of TP53 by MDM2
in smooth muscle cells. Overexpression of p55γ dramatically
reduced the proliferation of VSMCs in culture, increased TP53
protein levels and significantly decreased TP53 ubiquitination.
This demonstrates that p55γ activates and stabilizes TP53 by
attenuating the capacity of MDM2 to bind to TP53. In vivo,
delivery of p55γ by adenoviral infection reduced the production
of neointima formation post artery injury (Li et al., 2015).
Together these studies indicate that enhancement of MDM2-
TP53 interaction supports vascular smooth muscle hypertrophy
during atherosclerosis.
Beyond TP53: HDAC1 as a Downstream Effector of
MDM2 in Smooth Muscle Cells
MDM2 is also suggested to play an important role in smooth
muscle biology independently of TP53. In fact, MDM2 could
mediate vascular calcification through a mechanism involving
the ubiquitination of HDAC1 (Kwon et al., 2016). Vascular
calcification, the deposition of calcium phosphate, is often
associated with the development of atherosclerosis (Giachelli,
2003). Treatment of SMCs with Pi induces calcification. Kwon
and colleagues showed that Pi treatment induced the proteasomal
degradation of HDAC1, an event that preceded vascular
calcification. Pi treatment also upregulated MDM2 and triggered
the ubiquitination of HDAC1 by MDM2. Chemical inhibition
of MDM2 prevented vascular calcification. The silencing of
TP53 did not modulate vascular calcification in this study.
This suggests that vascular calcification induced by Pi-treatment
requires an MDM2/HDAC1 pathway.
Upstream Regulator of MDM2 in Smooth Muscle
Cells
Disturbances of the renin-angiotensin-aldosterone system are
part of the physiopathology of atherosclerosis, supporting VSMC
hypertrophy, proliferation and migration (Nehme and Zibara,
2017). Several pieces of evidence converge to suggest that
crosstalk between MDM2 and elements of the renin-angiotensin-
aldosterone system could support atherosclerosis by modulating
smooth muscle hypertrophy. First, angiotensin II can regulate
upstream kinases of MDM2, particularly PI3K and the ERK
(Saward and Zahradka, 1997; Li and Malik, 2005; Cooper et al.,
2007; Bunni et al., 2011). While the effect of angiotensin II
on MDM2 activity in VSMCs has not been directly examined,
it is plausible that phosphorylation of MDM2 by Akt or ERK
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promotes VSMC proliferation. Aldosterone stimulation of MR
significantly increased the expression of MDM2 protein in
VSMCs (Nakamura et al., 2006; Yan et al., 2018). In vivo, chronic
treatment of rats with aldosterone increased MDM2 protein
level as well as smooth muscle cell proliferation and collagen
deposition in the aorta. The silencing of MDM2 significantly
reduced smooth muscle cell proliferation. These effects were
prevented by eplerenone, an inhibitor of MR. This supports the
idea that MDM2 expression is upregulated by aldosterone, then
contributing to VSMC hypertrophy (Yan et al., 2018).
The CaM pathway is another strong regulator of smooth
muscle hypertrophy, mediating neointimal proliferation after
vascular injury (Li and Malik, 2005; Bouallegue et al., 2009; Li
et al., 2015). After carotid injury, Akt-dependent phosphorylation
of MDM2 on residue serine 166 was significantly reduced in
mice null for CaMKII-δ compared to wild-type mice (Li et al.,
2011). Less binding between TP53 and MDM2 was observed
in VSMC lacking the CaMKII-δ protein. Thus, CaMKII-
δ appears to function as an upstream regulator of MDM2
activity in smooth muscle cells. Since CaMKII-δ-KO mice
presented with less neointima thickening than wild-type mice,
this incriminates CaMKII-δ in provoking VSMC proliferation
and neointimal formation, potentially involving activation of the
Akt/MDM2 pathway.
Role of the MDM2 Pathway in
Cardiomyocytes
MDM2 plays an important role in maintaining cardiac function
by controlling cellular processes and the stress response
in cardiomyocytes.
MDM2 and the Cardiomyocyte Response to
Hypoxia/Reoxygenation
Toth et al. (2006) demonstrated that cardiomyocytes
overexpressing MDM2 acquired resistance to hypoxia/
reoxygenation-induced apoptosis. Overexpression of MDM2
by adenoviral infection protected primary cardiomyocytes in
culture from apoptosis following 12 h of hypoxia and following
hypoxia/reoxygenation (12 h of hypoxia followed by 16 h of
re-oxygenation). Chemical inhibition of MDM2 by PNC-28,
a peptide that mimics the MDM2-binding domain of TP53,
resulted in elevated TP53 levels and increased apoptosis under
normoxia, hypoxia, and hypoxia/reoxygenation conditions. This
suggests that MDM2 promotes cardiomyocyte survival in vitro
after hypoxia/reoxygenation. Toth et al. (2006) also showed
that MDM2 overexpression prevented hypertrophy of primary
cardiomyocytes following endothelin-1 or phenylephrine
treatment. These in vitro results are well aligned with the
observations these authors made in vivo that the heart of
MDM2 hypomorphic mice had cardiomyocytes with increased
cross-sectional areas and an increased area of infarction after
ischemia/reperfusion (Toth et al., 2006).
MDM2 and the Oxidative Stress in Cardiomyoctyes
During oxidative stress, MDM2 might exert both pro-apoptotic
and anti-apoptotic functions in cardiomyocytes. Pikkarainen
et al. (2009) reported an increased MDM2 expression after
oxidative stress. They found that knockdown of MDM2 with
an antisense strategy resulted in an increased level of caspase
3, supporting the notion that MDM2 protects against oxidative
stress in cardiomyocytes (Pikkarainen et al., 2009). Unexpectedly,
Foo et al. (2007) colleagues demonstrated that MDM2 induced
ARC protein degradation directly through its role as an E3
ubiquitin ligase. ARC is a 22 kDa anti-apoptotic protein that
is found abundantly in cardiomyocytes and skeletal myocytes
(Koseki et al., 1998). Overexpression of MDM2 led to a decrease
in ARC levels. H2O2 significantly upregulated MDM2 protein
levels and induced significant apoptotic (50–60%) cell death
in cardiomyocytes. This was associated with a time-dependent
decrease in ARC protein levels. This was due to an MDM2-
dependent degradation of ARC. ARC expression was maintained
in MDM2/TP53 double knockout cardiomyocytes, while the
reintroduction of MDM2 restored ARC degradation, suggesting
a TP53-independent function of MDM2. Foo et al. (2007)
study supports a pro-apoptotic role for MDM2 in embryonic
cardiomyocytes through its regulation of ARC. It is plausible
that MDM2 regulates both TP53-dependent and independent
pathways to determine the fate of cardiomyocytes after oxidative
stress. Further investigations are required to fully elucidate the
role of MDM2 in cardiomyocytes during oxidative stress.
MDM2 and the Regulation of the β-Adrenergic
Signals
MDM2 can regulate the β-AR signal in cardiomyocytes in
a TP53-independent manner that involves G Protein-Coupled
Receptor Kinase 2 (GRK2) and β-arrestin2 (Li et al., 2009; Jean-
Charles et al., 2016, 2017). The β-arrestin and GRK protein
families are multi-functional proteins well known for their roles
in desensitizing β-AR signaling by blocking G protein coupling,
ultimately controlling contractility. In cardiomyocytes, MDM2
can bind and ubiquitinate both GRK2 and β-arrestin2 (Li et al.,
2009; Shenoy et al., 2009). While ubiquitination of GRK2 marks it
for degradation by the proteasomes, ubiquitination of β-arrestin2
facilitates its binding to signaling kinases rather than promoting
its degradation (Shenoy et al., 2007; Jean-Charles et al., 2016).
Cardiomyocytes harboring a double knock-down for Mdm2 and
Trp53 have an impairment of Ca2+ handling after stimulation
with the β-agonist isoproterenol (Jean-Charles et al., 2017). The
polyubiquitination of GRK2 was decreased in the hearts of mice
harboring a cardiomyocyte-specific double knockdown of Mdm2
and Trp53, leading to an increase in GRK2 protein levels. These
effects were associated with impaired contractility. Since the
delivery of the Mdm2 gene rescued the cardiac contractility,
it appears that MDM2 is required for proper signaling of the
β-adrenergic receptor in cardiomyocytes (Jean-Charles et al.,
2017). Therefore, in cardiomyocytes, proper control of MDM2
interaction with TP53 and other binding partners might be
important to fine-tune survival, hypertrophy, and sensitivity to
β-adrenergic signals.
Summary of Knowledge Gained About
the Role of MDM2 in Cardiovascular Cell
Types
Due to the role of MDM2 as a negative regulator of TP53, it
is not surprising that in vitro data support a pro-survival role
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for MDM2 in endothelial cells, VSMCs and cardiomyocytes.
However, MDM2 has functions that are independent of
TP53 in these cells.
In smooth muscle cells, pro-atherogenic stimuli appear to
upregulate MDM2. This upregulation of MDM2 might lead to
unwanted proliferation and calcification through the inhibition
of TP53 and HDAC1 activities. These actions of MDM2 would
ultimately facilitate atherosclerosis. In endothelial cells, MDM2
is crucial to survival and migration, potentially determining the
capacity of endothelial cells to initiate angiogenesis. Not only
does MDM2 reduce TP53 function to support survival, but it also
has a dichotomous action on VEGF-A signals. MDM2 supports
VEGF-A expression and is also able to sense this proangiogenic
signal to modulate endothelial cell gene expression. Finally,
in cardiomyocytes, MDM2 is a crucial regulator of the stress
response through mechanisms both dependent and independent
of TP53. More importantly, MDM2 also controls hypertrophy
and the sensitivity to β-adrenergic signals.
CONCLUSIVE REMARKS
Considering the number of small MDM2 inhibitors that
are currently under clinical trials, it is crucial to broaden
our knowledge of the physiological functions of MDM2 in
the cardiovascular system. Many upstream regulators and
downstream effectors of MDM2 have cardiovascular functions.
The phenotypes of MDM2 transgenic mouse models clearly
highlights how important MDM2 is in the cardiovascular
system. Studies performed on the three main cell types of the
cardiovascular system, i.e., endothelial cells, smooth muscle cells
and cardiomyocytes, further support a key role for MDM2.
It is highly plausible that MDM2 acts as a central hub for
the cardiovascular stress response. How this multitasking E3
ubiquitin ligase operates to coordinate this stress response in
the different cells present in the cardiovascular system remains
largely unclear. Further investigations are warranted to elucidate
how MDM2 are differentially regulated in the cardiovascular
system in the context of human health and disease. By delving
more into the study of the cardiovascular functions of MDM2,
researchers could open new avenues for the treatment and the
prevention of cardiovascular diseases, even for the development
of cancer treatments where cardiovascular toxicity is curtailed.
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